Standard
Neoadjuvant chemotherapy as ovarian cancer treatment: ever more used with major regional differences. / Fagö-Olsen, Carsten L; Ottesen, Bent; Kehlet, Henrik; Markauskas, Algirdas; Mosgaard, Berit J; Ottosen, Christian; Søgaard, Charlotte; Søgaard-Andersen, Erik; Høgdall, Claus.
I:
Danish Medical Journal, Bind 59, Nr. 8, 2012, s. A4477.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
Fagö-Olsen, CL, Ottesen, B
, Kehlet, H, Markauskas, A, Mosgaard, BJ, Ottosen, C, Søgaard, C, Søgaard-Andersen, E
& Høgdall, C 2012, '
Neoadjuvant chemotherapy as ovarian cancer treatment: ever more used with major regional differences',
Danish Medical Journal, bind 59, nr. 8, s. A4477. <
http://www.ncbi.nlm.nih.gov/pubmed/?term=22849978>
APA
Fagö-Olsen, C. L., Ottesen, B.
, Kehlet, H., Markauskas, A., Mosgaard, B. J., Ottosen, C., Søgaard, C., Søgaard-Andersen, E.
, & Høgdall, C. (2012).
Neoadjuvant chemotherapy as ovarian cancer treatment: ever more used with major regional differences.
Danish Medical Journal,
59(8), A4477.
http://www.ncbi.nlm.nih.gov/pubmed/?term=22849978Vancouver
Fagö-Olsen CL, Ottesen B, Kehlet H, Markauskas A, Mosgaard BJ, Ottosen C o.a. Neoadjuvant chemotherapy as ovarian cancer treatment: ever more used with major regional differences. Danish Medical Journal. 2012;59(8):A4477.
Author
Fagö-Olsen, Carsten L ; Ottesen, Bent ; Kehlet, Henrik ; Markauskas, Algirdas ; Mosgaard, Berit J ; Ottosen, Christian ; Søgaard, Charlotte ; Søgaard-Andersen, Erik ; Høgdall, Claus. / Neoadjuvant chemotherapy as ovarian cancer treatment: ever more used with major regional differences. I: Danish Medical Journal. 2012 ; Bind 59, Nr. 8. s. A4477.
Bibtex
@article{9e2b174ac9714117866d4f1b88115a5a,
title = "Neoadjuvant chemotherapy as ovarian cancer treatment: ever more used with major regional differences",
abstract = "The traditional first-line treatment for patients with advanced ovarian cancer with primary debulking surgery (PDS) and adjuvant chemotherapy is controversial as some authors report a potential benefit from the alternative treatment with neoadjuvant chemotherapy (NACT) and interval debulking surgery. The aim of this study was to investigate the use of NACT in Denmark in regard to increased use and regional differences.",
author = "Fag{\"o}-Olsen, {Carsten L} and Bent Ottesen and Henrik Kehlet and Algirdas Markauskas and Mosgaard, {Berit J} and Christian Ottosen and Charlotte S{\o}gaard and Erik S{\o}gaard-Andersen and Claus H{\o}gdall",
year = "2012",
language = "English",
volume = "59",
pages = "A4477",
journal = "Danish Medical Journal",
issn = "2245-1919",
publisher = "Almindelige Danske Laegeforening",
number = "8",
}
RIS
TY - JOUR
T1 - Neoadjuvant chemotherapy as ovarian cancer treatment: ever more used with major regional differences
AU - Fagö-Olsen, Carsten L
AU - Ottesen, Bent
AU - Kehlet, Henrik
AU - Markauskas, Algirdas
AU - Mosgaard, Berit J
AU - Ottosen, Christian
AU - Søgaard, Charlotte
AU - Søgaard-Andersen, Erik
AU - Høgdall, Claus
PY - 2012
Y1 - 2012
N2 - The traditional first-line treatment for patients with advanced ovarian cancer with primary debulking surgery (PDS) and adjuvant chemotherapy is controversial as some authors report a potential benefit from the alternative treatment with neoadjuvant chemotherapy (NACT) and interval debulking surgery. The aim of this study was to investigate the use of NACT in Denmark in regard to increased use and regional differences.
AB - The traditional first-line treatment for patients with advanced ovarian cancer with primary debulking surgery (PDS) and adjuvant chemotherapy is controversial as some authors report a potential benefit from the alternative treatment with neoadjuvant chemotherapy (NACT) and interval debulking surgery. The aim of this study was to investigate the use of NACT in Denmark in regard to increased use and regional differences.
M3 - Journal article
VL - 59
SP - A4477
JO - Danish Medical Journal
JF - Danish Medical Journal
SN - 2245-1919
IS - 8
ER -
